Literature DB >> 7773297

Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.

P L Tavormina1, R Shiang, L M Thompson, Y Z Zhu, D J Wilkin, R S Lachman, W R Wilcox, D L Rimoin, D H Cohn, J J Wasmuth.   

Abstract

Thanatophoric dysplasia (TD), the most common neonatal lethal skeletal dysplasia, affects one out of 20,000 live births. Affected individuals display features similar to those seen in homozygous achondroplasia. Mutations causing achondroplasia are in FGFR3, suggesting that mutations in this gene may cause TD. A sporadic mutation causing a Lys650Glu change in the tyrosine kinase domain of FGFR3 was found in 16 of 16 individuals with one type of TD. Of 39 individuals with a second type of TD, 22 had a mutation causing an Arg248Cys change and one had a Ser371Cys substitution, both in the extracellular region of the protein. None of these mutations were found in 50 controls showing that mutations affecting different functional domains of FGFR3 cause different forms of this lethal disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773297     DOI: 10.1038/ng0395-321

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  123 in total

Review 1.  Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Authors:  William A Horton; Gregory P Lunstrum
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

2.  Phenotypic expression of the fibroblast growth factor receptor 3 (FGFR3) mutation P250R in a large craniosynostosis family.

Authors:  A Golla; P Lichmer; S von Gernet; A Winterpacht; J Fairley; J Murken; S Schuffenhauer
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

3.  Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation.

Authors:  Anette Bygum; Christina R Fagerberg; Ole J Clemmensen; Britta Fiebig; Christian Hafner
Journal:  BMC Med Genet       Date:  2011-06-05       Impact factor: 2.103

Review 4.  Fibroblast growth factor receptor mutations and craniosynostosis: three receptors, five syndromes.

Authors:  A O Wilkie
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

5.  Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway.

Authors:  S Murakami; M Kan; W L McKeehan; B de Crombrugghe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 6.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

7.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.

Authors:  Christian Hafner; Agustí Toll; Alejandro Fernández-Casado; Julie Earl; Miriam Marqués; Francesco Acquadro; Marinela Méndez-Pertuz; Miguel Urioste; Núria Malats; Julie E Burns; Margaret A Knowles; Juan C Cigudosa; Arndt Hartmann; Thomas Vogt; Michael Landthaler; Ramón M Pujol; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

8.  Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?

Authors:  W Reardon; A Smith; J W Honour; P Hindmarsh; D Das; G Rumsby; I Nelson; S Malcolm; L Adès; D Sillence; D Kumar; C DeLozier-Blanchet; S McKee; T Kelly; W L McKeehan; M Baraitser; R M Winter
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

9.  KinMutBase, a database of human disease-causing protein kinase mutations.

Authors:  K A Stenberg; P T Riikonen; M Vihinen
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 10.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.